Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02863991 · ClinicalTrials.gov registry record · Phase 1
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Jazz Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT02863991 is a Phase 1 study that was terminated before completion, run by Jazz Pharmaceuticals. The registered enrollment target is 17 participants.
The verdict
NCT02863991, a Phase 1 study, was terminated before completion, sponsored by Jazz Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This was a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone in adults with relapsed/refractory multiple myeloma. The primary objective of this study was to evaluate the antitumor efficacy of ONC201. Note: This study was completed by predecessor company, Oncoceutics, Inc.
Interventions
- DRUG Dexamethasone
- DRUG ONC201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-04-19 |
| Est. Completion | 2019-12-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02863991
The ClinicalTrials.gov registry entry for NCT02863991 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT02863991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02863991 about?
NCT02863991 is a clinical study titled "Oral ONC201 in Relapsed/Refractory Multiple Myeloma". This was a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone in adults with relapsed/refractory multiple myeloma. The primary objective of this study was to evaluate the antitumor efficacy of ONC201. Note: This study was completed by predeces...
What is the current status of trial NCT02863991?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2017-04-19. Estimated completion is 2019-12-16.
What interventions are being tested in trial NCT02863991?
The interventions under investigation include: Dexamethasone (DRUG), ONC201 (DRUG).
Who is sponsoring clinical trial NCT02863991?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.